US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Bulletin from the extraordinary general meeting, and the second control meeting, in Qlife Holding AB on 8 November 2024

Today, on 8 November 2024, an extraordinary general meeting, and the second control meeting, was held in Qlife Holding AB. A summary of the adopted resolutions follows below.Resolution on whether the company shall enter into liquidation or continue its operations It was noted that the second control balance sheet shows that the company's total equity is fully restored. On that basis, the extraordinary general meeting resolved in accordance with the primary proposal from the board of directors that the company’s operations shall be continued. Resolution on amendment of the Articles of

QLIFE HOLDING AB, Interim Report Q3, July to September 2024

Finally thereFinancial summary – third quarter 2024 · Revenue in the period amounted to kSEK 0 (45). · EBITDA for the period amounted to kSEK –27,151 (-6,660), and net loss kSEK – 28,087 (-8,926). · The total cash flow in the third quarter amounted to kSEK 2,979 (-3,631). · Earnings per share before/after dilution for the quarter amounted to SEK -0.12 (-0.01), calculated on weighted average number of shares in the period. Significant events – third quarter 2024 · On 2. July Qlife announces that it has participated a research trial in the USA for people living with PKU (

Kallelse till extra bolagsstämma i Qlife Holding AB tillika andra kontrollstämma

Aktieägarna i Qlife Holding AB, org.nr 559224-8040 (”Bolaget”), kallas till extra bolagsstämma, tillika andra kontrollstämma, den 8 november 2024 kl. 10.00 i Moll Wendén Advokatbyrås lokaler på Stortorget 8 i Malmö.Rätt att delta och anmälan Den som önskar delta i stämman ska: · dels vara upptagen som aktieägare i den av Euroclear Sweden AB framställda aktieboken avseende förhållanden på avstämningsdagen som är den 31 oktober 2024 · dels anmäla sig till stämman senast den 1 november 2024. Anmälan görs per post till Qlife Holding AB, Extra bolagsstämma, Redaregatan 48, 252 36

Qlife withdraws proposal to change company name

Qlife Holding AB (publ) (“Qlife” or the “Company”) has decided to withdraw its proposal to change the Company’s name as the intended name, Egoo Health AB, cannot be registered by the Swedish Companies Registration Office (Bolagsverket).On 29 August 2024, Qlife announced its intention to change the Company’s name to Egoo Health AB as part of a broader rebranding initiative. However, the Swedish Companies Registration Office has informed the Company that Egoo Health AB cannot be registered. As a result, Qlife has decided to withdraw the proposal to change its name. The Company remains

Qlife starts sales of its PHE rare disease test, addressing an unmet need in the at-home testing market worth SEK 2.5 billion

Resent due to technical problems news distributor. Since its inception, Qlife has been developing the Phenylalanine (PHE) test capsule and is now prepared to offer it for sale to individuals with Phenylketonuria. Initially, the at-home PHE test will be available as a research-use-only (CE-RUO) product, designed to supplement existing testing routines until it receives full regulatory approval. The company plans to begin the process of registering the test as an in-vitro diagnostic (IVD) later this year, starting in the UK and expanding to the EU and other markets.An at-home PHE test will

Qlife starts sales of its PHE rare disease test, addressing an unmet need in the at-home testing market worth SEK 2.5 billion

Since its inception, Qlife has been developing the Phenylalanine (PHE) test capsule and is now prepared to offer it for sale to individuals with Phenylketonuria. Initially, the at-home PHE test will be available as a research-use-only (CE-RUO) product, designed to supplement existing testing routines until it receives full regulatory approval. The company plans to begin the process of registering the test as an in-vitro diagnostic (IVD) later this year, starting in the UK and expanding to the EU and other markets.An at-home PHE test will significantly improve the quality of life for people

Qlife is pleased to announce that Peter Warthoe will return to the management group as Chief Scientific Officer

Peter Warthoe, one of the three founders of Qlife, is back in his management role as Chief Scientific Officer and will focus on the company’s continued quest to bring the Egoo Health self-testing diagnostic platform on the market.Peter Warthoe is one of the co-founders of Qlife but decided a few years ago to step out of the management role to focus more on his scientific projects. Given the company’s new lean structure and its focus on supporting its Chinese partner’s effort to bring products through clinical trials and to the market in China, Peter Warthoe will take up his role as CSO and

Qlife Holding AB (publ) is pleased to announce that it publishes a second balance sheet for liquidation purposes showing that the Company's total equity exceeds the registered share capital

Qlife Holding AB (publ) (“Qlife” or the “Company”) has, in accordance with Chapter 25, Section 16 of the Swedish Companies Act (“ABL”), prepared a second balance sheet for liquidation purposes, which has been reviewed by the Company's auditor. The balance sheet shows that the Company's total equity exceeds the registered share capital.On 21 March 2024, the Company presented a balance sheet for liquidation purposes, showing that the equity was less than half of the registered share capital. On 28 March 2024, Qlife announced that the rights issue, approved by the extraordinary general meeting

Production of Egoo consumables now established in China to support on-going clinical trials and future sales

Qlife Holding AB (publ) (“Qlife” or the “Company”) recently announced a restructuring and new financing to support its strategic goals. The Company is pleased to report that its operational plan with its partner Hipro Biotechnology (“Hipro”) in China is progressing as planned, with the production of Egoo consumables—EgooCapsule (Biochemistry reagents) and EgooCollect (Blood-to-Plasma filtration)—now established at the partner site. The target is to reach a capacity of 1 million in 2025 and 10 million within 3 years. This production capability will support clinical trial efforts and future

Qlife provides strategic business update and plans rebranding as 'Egoo Health' – a new era begins

Qlife Holding AB (publ) ("Qlife" or the "Company") is pleased to announce a comprehensive business update in light of recent strategic developments, including directed issues of shares and warrants, the repurchase of key assets from the estate of Qlife ApS, and an upcoming rebranding initiative, signaling the dawn of a new chapter for the Company.As outlined in the press release dated 29 August 2024, Qlife has successfully executed directed issues of shares and warrants pursuant to the authority granted by the annual general meeting 2024. These directed issues facilitate the repurchase of

Qlife acquires the assets of Qlife ApS, carries out directed issues of a total of approx. MSEK 6.90 and proposal of directed issues of approx. MSEK 5.05

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, JAPAN, HONG KONG, SOUTH KOREA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, RUSSIA OR BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.Qlife Holding AB (publ) (“Qlife” or the “Company”) announces the acquisition of the assets of the Company's subsidiary Qlife ApS in bankruptcy, including goodwill and other intangible rights inventory, equipment, inventory and

QLIFE HOLDING AB, Interim Report Q2, April to June 2024

Restructuring the companyFinancial summary – second quarter 2024 · Revenue in the period amounted to kSEK 39 (46). · EBITDA for the period amounted to kSEK –8,002 (-16,287), and net loss kSEK –12,979 (-22,703). · The total cash flow in the second quarter amounted to kSEK -4,809 (7,894). · Earnings per share before/after dilution for the quarter amounted to SEK -0.01 (-0.05), calculated on weighted average number of shares in the period. Significant events – second quarter of 2024 · On 4. April Qlife enters its Danish subsidiary Qlife Aps into reconstruction. Under

Qlife Holding AB (publ) meddelar omräkning av teckningsoptioner

Med anledning av sammanläggningen av aktier i Qlife Holding AB (publ) (”Qlife” eller ”Bolaget”) som beslutades på årsstämman den 26 juni 2024, har omräkning gjorts i enlighet med optionsvillkoren avseende teckningskurs och antalet aktier som varje teckningsoption av serie TO 5 ger rätt att teckna.Årsstämman i Qlife beslutade den 26 juni 2024 om sammanläggning av aktier 1:2000, innebärande att 2000 befintliga aktier läggs samman till 1 aktie. Styrelsen i Qlife fastställde avstämningsdagen för sammanläggningen till den 31 juli. Med anledning av sammanläggningen har en omräkning genomförts

Qlife Holding AB’s subsidiary Qlife ApS terminates corporate restructuring and files for bankruptcy. Qlife Holding AB investigates a capital raise and to submit an offer to repurchase the assets.

Qlife Holding AB ("Qlife" or the "Company") has today received information that Qlife ApS’s reconstructor will terminate the corporate restructuring. The board of directors has consequently today decided to file for bankruptcy for the subsidiary, Qlife ApS. On 4 April 2024, the Company announced that Qlife ApS was undergoing reconstruction to address creditor issues and to manage short-term liquidity. Since then, the Company has been seeking a long-term financing solution to facilitate the subsidiary's exit from reconstruction. As announced on June 6, 2024, the Company had entered into a non-

Avstämningsdag för sammanläggning av aktier i Qlife Holding AB

Styrelsen i Qlife Holding AB (publ) (”Qlife” eller ”Bolaget”) har, med stöd av bemyndigandet från årsstämman som hölls den 26 juni 2024, beslutat att avstämningsdag för sammanläggning av aktier ska vara den 31 juli 2024. Genom sammanläggningen ska tvåtusen (2 000) befintliga aktier läggas samman till en (1) aktie.Sammanläggning av aktier Årsstämman beslutade den 26 juni 2024 om sammanläggning av aktier varigenom tvåtusen (2 000) befintliga aktier läggs samman till en (1) aktie. För att möjliggöra sammanläggningen beslutades även om ändring av bolagsordningens gränser för antalet aktier.

Qlife participates research trial for people living with PKU and gets positive data

Qlife has participated a research trial at Emory University (USA) focused on young women living with PKU (phenylketonuria) and made Egoo systems available for on-site testing of the PHE test (phenylalanine).For a couple of weeks during June Qlife was invited to participate Emory’s Metabolic Camp and run a research trial with the aim of making a comparison study of blood data on Egoo compared to data from normal laboratory routines. The outcome was positive since data correlated very well. The research trial was likewise focused on the usability aspect of the young people getting to know and

Kommuniké från årsstämma 2024 i Qlife Holding AB

Qlife Holding AB höll den 26 juni 2024 årsstämma varvid i huvudsak följande beslut fattades. Fastställande av räkenskaper samt resultatdisposition Årsstämman beslutade att fastställa resultat- och balansräkning samt koncernresultat- och koncernbalansräkning. Årsstämman beslutade även att disponera över bolagets resultat i enlighet med styrelsens förslag innebärande att någon utdelning inte lämnas och att bolagets medel till förfogande överförs i ny räkning. Ansvarsfrihet Årsstämman beslutade att bevilja styrelseledamöterna och verkställande direktören ansvarsfrihet för

Qlife Holding AB loses arbitration proceedings against Aidian

On 13 March 2023, Qlife Holding AB (“Qlife” or the “Company”) announced that Aidian Oy had initiated arbitration proceedings against Qlife’s wholly owned subsidiary Qlife ApS regarding payment of unpaid invoices for various products and services. Today, Qlife has received the judgment in the arbitration proceedings. Qlife ApS has been ordered to pay approximately MEUR 0.80 to Aidian for its claim together with a contractually agreed annual penal interest of 10.00 per cent per annum from the due dates onward until payment, and approximately MEUR 0.26 to Aidian for its legal fees together

Qlife Holding AB publishes information by reason of ongoing negotiations with Atlas Special Opportunities, LLC, regarding a financing solution

Qlife Holding AB (“Qlife” or the “Company”) and Atlas Special Opportunities, LLC (“Atlas”), have entered into a non-binding term sheet on 13 May 2024. According to the term sheet, Atlas will fund the Company with up to SEK 30.00 million in ten (10) tranches of different sizes. Further, the called loan amounts can be converted into new shares. Qlife will communicate the outcome of the ongoing negotiations to the market as soon as concrete information becomes available.

Qlife Holding AB: The exercise period for warrants series TO 4 in Qlife Holding begins today

The exercise period for warrants series TO 4 that were issued in conjunction with Qlife Holding AB's ("Qlife" or the "Company") rights issue of units in February 2024 (the "Rights Issue") begins today, 7 June 2024.Terms for warrants series TO 4 in brief: · The exercise price is SEK 0.02 per share. · The exercise period runs from 7 – 21 June 2024. · Each warrant entitles the holder to subscribe for one (1) share. Upon exercise of all 1,048,696,624 outstanding warrants, 1,048,696,624 shares will be issued. · If the warrants are fully exercised, the Company will receive

Qlife starts clinical trial in China with first biomarker on Egoo Health

Qlife and its partner Hipro Biotechnology have validated performance of the first biomarker C-Reactive Protein and are now starting clinical testing.Since last year, Qlife has worked diligently towards transferring the Egoo Health platform to Hipro in China to setup pilot production of consumables, validate performance with Hipro reagents, and move the first target assay into clinical testing. For Qlife, this constitutes an important step towards getting regulatory approval of Egoo Health in China and starting sales. C-Reactive Protein is one of the most used biomarkers for inflammatory

QLIFE HOLDING AB, Interim Report Q1, January to March 2024

Standing firm and moving forwardFinancial summary – first quarter 2024 · Revenue in the period amounted to kSEK 0 (123). No revenue of Egoo.Health devices and capsules for the device. · EBITDA for the period amounted to kSEK –11,716 (-11,697), and net loss kSEK –8,351(-16,780). · The total cash flow in the first quarter amounted to kSEK 2,714 (-12,110). · Earnings per share before/after dilution for the quarter amounted to SEK -0.01 (-0.73), calculated on weighted average number of shares in the period. Significant events – first quarter of 2024 · Qlife carries out a

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media